ACPA-positive RA and ACPA-negative RA respond differently to the traditional DMARD methotrexate, which can reduce the possibility of progression from undifferentiated arthritis to RA in ACPA-positive patients. Here, PRTN3 is linked to rheumatoid arthritis.